As more people turn to telehealth for GLP-1s, one type of pharmacy is coming under scrutiny.

A strategic letter of intent with an established U.S. 503A compounding pharmacy gives The More Life Company (CSE: MLCO, OTC: ...

The More Life Company (MLCO.CN) entered into a non-binding letter of intent (LOI) with a US 503A compounding pharmacy to advance the development, compounding and commercialization of its Quicksome ...

As certain prescription medicines gain increasing attention online, concerns have also emerged over Filipinos obtaining ...

A child who cannot swallow a pill. A patient allergic to an ingredient in a standard prescription. A medication that manufacturers have stopped making altogether. These are the kinds of challenges ...

Food and Drug Administration scientists and some medical experts have raised alarms about increasing access to certain ...

The More Life Company Corp. (the “Company” or “MLCO”), (CSE: MLCO) (OTC: TMLCF) is pleased to announce that it has entered into a strategic letter of intent (“LOI”) with an established U.S. 503A ...

The FDA took issue with the volume of GLP-1 drugs that Empower produces, suggesting in the warning letter that the changes do not serve legitimate medical needs.

FDA inspectors found evidence that the compounding pharmacy was making versions of Eli Lilly’s tirzepatide and Novo’s ...

LTR Pharma Limited (ASX:LTP) has confirmed the first ROXUS® prescriptions have been fulfilled in the United States. ROXUS is a prescription nasal spray that delivers vardenafil, an ED medicine used in ...